Maintenance Intravenous Iron Therapy in Hepmodialysis Patients Receiving Recombinant Human Erythropoientin
Iron Supplementation is crucial in raising hematocrit as well as dosage saving for recombinant human erythropoietin therapy (rHuEPO) in maintenance hemodialysis patients. Intravenous iron has proved to be both safe and efficacious in this patient′s population. However, the exact iron requ...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
1999-01-01
|
| Series: | Saudi Journal of Kidney Diseases and Transplantation |
| Subjects: | |
| Online Access: | http://www.sjkdt.org/article.asp?issn=1319-2442;year=1999;volume=10;issue=1;spage=21;epage=25;aulast=Romeh |
| _version_ | 1819103360763035648 |
|---|---|
| author | Romeh Saleh Huraib Sameer Murray Noeline Tanimu Danlami Flaiw Ahmed Iqbal Asmir Al Ghamdi Ghormullah Quadri Khaja |
| author_facet | Romeh Saleh Huraib Sameer Murray Noeline Tanimu Danlami Flaiw Ahmed Iqbal Asmir Al Ghamdi Ghormullah Quadri Khaja |
| author_sort | Romeh Saleh |
| collection | DOAJ |
| description | Iron Supplementation is crucial in raising hematocrit as well as dosage saving for recombinant human erythropoietin therapy (rHuEPO) in maintenance hemodialysis patients. Intravenous iron has proved to be both safe and efficacious in this patient′s population. However, the exact iron requirement has not been worked our. In this study we found that 1000 mg of element iron (given as iron saccharate) per moth was effective in maintaining hematocrit and hemoglobin at 33% and 110 gm/L respectively, and reducing the erythropoietin (EPO) dosage by about 20% in maintenance hemodialysis patients who were iron-replete. The serum ferritin increased from 219±144 to 320±234 µg/L (P< 0.05). There were no major side effects and patients tolerated the monthly iron therapy well. Our study suggests that intravenous iron saccharate (100 mg/month) is effective and safe in patients on maintenance hemodialysis receiving RHUEPO. |
| first_indexed | 2024-12-22T01:49:14Z |
| format | Article |
| id | doaj.art-d41d5ffdccab4611a6720881a86f7cec |
| institution | Directory Open Access Journal |
| issn | 1319-2442 |
| language | English |
| last_indexed | 2024-12-22T01:49:14Z |
| publishDate | 1999-01-01 |
| publisher | Wolters Kluwer Medknow Publications |
| record_format | Article |
| series | Saudi Journal of Kidney Diseases and Transplantation |
| spelling | doaj.art-d41d5ffdccab4611a6720881a86f7cec2022-12-21T18:42:58ZengWolters Kluwer Medknow PublicationsSaudi Journal of Kidney Diseases and Transplantation1319-24421999-01-011012125Maintenance Intravenous Iron Therapy in Hepmodialysis Patients Receiving Recombinant Human ErythropoientinRomeh SalehHuraib SameerMurray NoelineTanimu DanlamiFlaiw AhmedIqbal AsmirAl Ghamdi GhormullahQuadri KhajaIron Supplementation is crucial in raising hematocrit as well as dosage saving for recombinant human erythropoietin therapy (rHuEPO) in maintenance hemodialysis patients. Intravenous iron has proved to be both safe and efficacious in this patient′s population. However, the exact iron requirement has not been worked our. In this study we found that 1000 mg of element iron (given as iron saccharate) per moth was effective in maintaining hematocrit and hemoglobin at 33% and 110 gm/L respectively, and reducing the erythropoietin (EPO) dosage by about 20% in maintenance hemodialysis patients who were iron-replete. The serum ferritin increased from 219±144 to 320±234 µg/L (P< 0.05). There were no major side effects and patients tolerated the monthly iron therapy well. Our study suggests that intravenous iron saccharate (100 mg/month) is effective and safe in patients on maintenance hemodialysis receiving RHUEPO.http://www.sjkdt.org/article.asp?issn=1319-2442;year=1999;volume=10;issue=1;spage=21;epage=25;aulast=RomehRecombinant human erythropoietinMaintenance hemodialysisIntravenous iron therapySerum ferritin. |
| spellingShingle | Romeh Saleh Huraib Sameer Murray Noeline Tanimu Danlami Flaiw Ahmed Iqbal Asmir Al Ghamdi Ghormullah Quadri Khaja Maintenance Intravenous Iron Therapy in Hepmodialysis Patients Receiving Recombinant Human Erythropoientin Saudi Journal of Kidney Diseases and Transplantation Recombinant human erythropoietin Maintenance hemodialysis Intravenous iron therapy Serum ferritin. |
| title | Maintenance Intravenous Iron Therapy in Hepmodialysis Patients Receiving Recombinant Human Erythropoientin |
| title_full | Maintenance Intravenous Iron Therapy in Hepmodialysis Patients Receiving Recombinant Human Erythropoientin |
| title_fullStr | Maintenance Intravenous Iron Therapy in Hepmodialysis Patients Receiving Recombinant Human Erythropoientin |
| title_full_unstemmed | Maintenance Intravenous Iron Therapy in Hepmodialysis Patients Receiving Recombinant Human Erythropoientin |
| title_short | Maintenance Intravenous Iron Therapy in Hepmodialysis Patients Receiving Recombinant Human Erythropoientin |
| title_sort | maintenance intravenous iron therapy in hepmodialysis patients receiving recombinant human erythropoientin |
| topic | Recombinant human erythropoietin Maintenance hemodialysis Intravenous iron therapy Serum ferritin. |
| url | http://www.sjkdt.org/article.asp?issn=1319-2442;year=1999;volume=10;issue=1;spage=21;epage=25;aulast=Romeh |
| work_keys_str_mv | AT romehsaleh maintenanceintravenousirontherapyinhepmodialysispatientsreceivingrecombinanthumanerythropoientin AT huraibsameer maintenanceintravenousirontherapyinhepmodialysispatientsreceivingrecombinanthumanerythropoientin AT murraynoeline maintenanceintravenousirontherapyinhepmodialysispatientsreceivingrecombinanthumanerythropoientin AT tanimudanlami maintenanceintravenousirontherapyinhepmodialysispatientsreceivingrecombinanthumanerythropoientin AT flaiwahmed maintenanceintravenousirontherapyinhepmodialysispatientsreceivingrecombinanthumanerythropoientin AT iqbalasmir maintenanceintravenousirontherapyinhepmodialysispatientsreceivingrecombinanthumanerythropoientin AT alghamdighormullah maintenanceintravenousirontherapyinhepmodialysispatientsreceivingrecombinanthumanerythropoientin AT quadrikhaja maintenanceintravenousirontherapyinhepmodialysispatientsreceivingrecombinanthumanerythropoientin |